title: Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
abstract: BACKGROUND
  Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative gastro-oesophageal reflux disease.
  
  
  OBJECTIVE
  To compare the efficacy of 'on-demand' treatment with esomeprazole 20 mg vs. continuous treatment with lansoprazole 15 mg daily in patients with endoscopy-negative gastro-oesophageal reflux disease.
  
  
  METHODS
  Endoscopy-negative gastro-oesophageal reflux disease patients who achieved complete resolution of heartburn after short-term (2-4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on-demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months.
  
  
  RESULTS
  Significantly more patients were willing to continue taking esomeprazole on-demand than lansoprazole continuous therapy after 6 months (93% vs. 88%; P = 0.02). This superior outcome was achieved despite patients on esomeprazole requiring medication only 38% as often as those on lansoprazole, leading to direct cost savings of more than one-third (36%). Furthermore, patients receiving esomeprazole 20 mg on-demand were more satisfied with their treatment after 1 month compared with patients taking lansoprazole 15 mg continuously.
  
  
  CONCLUSIONS
  In patients with endoscopy-negative gastro-oesophageal reflux disease, esomeprazole 20 mg on-demand is more acceptable to patients and is an economically more effective treatment than lansoprazole 15 mg continuously.
authors.affiliation: Castle Hill Hospital, Cottingham, Hull, UK. hhtsai@doctors.org.uk
authors.forename: H H
authors.initials: HH
authors.lastname: Tsai
authors.forename: R
authors.initials: R
authors.lastname: Chapman
authors.forename: A
authors.initials: A
authors.lastname: Shepherd
authors.forename: D
authors.initials: D
authors.lastname: McKeith
authors.forename: M
authors.initials: M
authors.lastname: Anderson
authors.forename: D
authors.initials: D
authors.lastname: Vearer
authors.forename: S
authors.initials: S
authors.lastname: Duggan
authors.forename: J P
authors.initials: JP
authors.lastname: Rosen
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D064098:Esomeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D064747:Lansoprazole; D008875:Middle Aged; D017060:Patient Satisfaction; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D064098:Esomeprazole